JP2004143049A - Method for purifying 5'-o-substituted thymidine - Google Patents

Method for purifying 5'-o-substituted thymidine Download PDF

Info

Publication number
JP2004143049A
JP2004143049A JP2002306776A JP2002306776A JP2004143049A JP 2004143049 A JP2004143049 A JP 2004143049A JP 2002306776 A JP2002306776 A JP 2002306776A JP 2002306776 A JP2002306776 A JP 2002306776A JP 2004143049 A JP2004143049 A JP 2004143049A
Authority
JP
Japan
Prior art keywords
group
thymidine
dimethoxytrityl
general formula
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002306776A
Other languages
Japanese (ja)
Other versions
JP4424900B2 (en
Inventor
Toshiyuki Kono
河野 敏之
Hironori Komatsu
小松 弘典
Daiki Ishibashi
石橋 大樹
Hiroharu Tanigawa
谷川 広晴
Katsutoshi Tsuchiya
土屋 克敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsui Chemicals Inc
Original Assignee
Mitsui Chemicals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsui Chemicals Inc filed Critical Mitsui Chemicals Inc
Priority to JP2002306776A priority Critical patent/JP4424900B2/en
Publication of JP2004143049A publication Critical patent/JP2004143049A/en
Application granted granted Critical
Publication of JP4424900B2 publication Critical patent/JP4424900B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Saccharide Compounds (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide an efficient method for purifying 5'-O-(4, 4'-dimethoxytrityl)thymidine designed to improve a conventional method for purifying the 5'-O-(4, 4'-dimethoxytrityl)thymidine because of an inefficient method for purification such as a recrystallization method, a column chromatographic method or a reprecipitating method using especially toxic benzene, chloroform or dichloromethane. <P>SOLUTION: The method for purifying the 5'-O-(4, 4'-dimethoxytrityl)thymidine is a method for purification by recrystallization with acetonitrile. Impurities are removed by the method for purification to purify the 5'-O-(4, 4'-dimethoxytrityl)thymidine to a high purity. Thereby, the 5'-O-(4, 4'-dimethoxytrityl)thymidine can readily be produced on a large scale by the method for purification. <P>COPYRIGHT: (C)2004,JPO

Description

【0001】
【発明の属する技術分野】
本発明は、5’−O−置換チミジンの精製方法に関する。
【0002】
【従来の技術】
近年、ゲノム創薬の進展に伴い、アンチセンスDNA医薬などが急速に開発されている。それに伴い、原料となるDNAオリゴマー、さらにオリゴマーの原料となる保護化デオキシヌクレオシド類の需要が増大している。一方で医薬品の用途には、含まれている不純物による副生成物の生成を極力抑制するため、非常に高純度の中間体製品を使用する必要がある。
【0003】
これまで、5’−O−(4,4’−ジメトキシトリチル)チミジンは、特開昭58−180500号公報、J.Am.Chem.Soc.,85,3821(1963)、蛋白質核酸酵素Vol.26,No.4,531(1981)などの例であきらかなとおり、ベンゼン或いはベンゼンとヘキサンなどの混合溶媒で再結晶法により精製されてきた。ベンゼンは特に有害であり将来の大量生産、大量供給においては非常に問題があるといわざるを得ない。また、実際に行った場合、ゲル化して溶媒と共に不純物を取り込むため実用的ではない。特表平11−511480号公報では、酢酸エチル/ヘキサンの混合溶媒で再結晶により精製しているが、酢酸エチルとヘキサンの量比を適切に調整することは工業的には困難で、量比を誤ると容易にオイル化したり、粘性のある沈殿を生じて精製を失敗しやすい。 Methods in Enzymology Vol.65 Nucleic Acids PartI(1980)などシリカゲルを用いたカラムクロマトグラフィーによる精製があるが、カラムクロマトグラフィーは、大量生産、大量供給には不向きである。また、溶離液に特に有害なクロロホルムを使用している。その他の精製方法として、懸濁法については、PCT出願WO200039138で、また、再沈殿法についてはPTC出願WO200075154で報告されているが、何れもが溶媒にジクロロメタンを使用している。また、混合溶媒で精製しているが、5’−O−(4,4’−ジメトキシトリチル)チミジンについて、可溶性溶媒と不溶性溶媒の混合であり、その量比を適切に調整することは工業的には困難で、量比を誤ると容易にオイル化したり、粘性のある沈殿を生じて精製を失敗しやすく、問題がある。
【0004】
そこで種々の溶媒を検討した結果、メチルイソブチルケトンや酢酸ブチルに代表されるカルボニル系溶媒を用いた場合、これまで報告例のなかった単一溶媒での再結晶が可能となり、しかも精製能が非常に高いことが判った。これら溶媒での精製法を用いれば、これまでには精製が困難だった5’位と3’位の両方にトリチル基が置換した不純物や3’位にトリチル基が置換した置換異性体の不純物が容易に除去できる。しかしながら、再結晶生成物は、メチルイソブチルケトンや酢酸ブチルなどの再結晶溶媒を抱接した結晶形で得られ、抱接溶媒の除去は通常の減圧乾燥などの方法では無理であった。
【0005】
【特許文献1】特開昭58−180500号公報
【0006】
【特許文献2】特表平11−511480号公報
【0007】
【特許文献3】PCT出願WO200039138公報
【0008】
【特許文献4】PTC出願WO200075154公報
【0009】
【非特許文献1】J.Am.Chem.Soc.,85,3821(1963)
【0010】
【非特許文献2】蛋白質核酸酵素Vol.26,No.4,531(1981)
【0011】
【非特許文献3】Methods in Enzymology Vol.65Nucleic Acids PartI(1980)
【0012】
【発明が解決しようとする課題】
従来の問題点を鑑み、効率的かつ特別な設備を必要としない、非常に高純度の5’−O−置換チミジンの製造法を提供することである。
【0013】
【課題を解決するための手段】
本発明者らは上記課題について鋭意検討した結果、5’−O−(4,4’−ジメトキシトリチル)チミジンが、アセトニトリルを用いる再結晶による精製法により精製可能で、さらに溶媒を抱接しないことを見出し、本発明を完成した。
【0014】
即ち、本発明は、以下の各態様を含む。
(1) 一般式〔1〕[化9]
【0015】
【化9】

Figure 2004143049
【0016】
(式中、R1は炭素数1〜4のアルキル基を表す。)で表される溶媒を用いて再結晶することを特徴とする、一般式〔2〕[化10]
【0017】
【化10】
Figure 2004143049
【0018】
(式中、R2は置換されてもよいトリチル基を、R3は水素原子または炭素数1〜4のアルキル基を、R4は水素原子、ハロゲン原子、もしくは置換されていてもよい水酸基を表す)で表される5’−O−置換チミジンの精製法。
(2) 一般式〔3〕[化11]
【0019】
【化11】
Figure 2004143049
【0020】
(式中、R5は炭素数1〜4のアルキル基を、R6は炭素数1〜4のアルキル基もしくは炭素数1〜4のアルコキシ基を表す)で表されるカルボニル系溶媒で再結晶を行った後、一般式〔1〕[化12]
【0021】
【化12】
Figure 2004143049
【0022】
(式中、R1は前記と同義である。)で表される溶媒を用いて再結晶することを特徴とする、一般式〔2〕[化13]
【0023】
【化13】
Figure 2004143049
【0024】
(式中、R2、R3およびR4は前記と同義である。)で表される5’−O−置換チミジンの精製法。
(3) 一般式〔4〕[化14]
【0025】
【化14】
Figure 2004143049
【0026】
(式中、mおよびnはそれぞれ独立して任意の整数、R2、R3、R4、R5およびR6は前記と同義である)で表される化合物を一般式〔1〕[化15]
【0027】
【化15】
Figure 2004143049
【0028】
(式中、R1は前記と同義である。)で表される溶媒を用いて再結晶することを特徴とする、一般式〔2〕[化16]
【0029】
【化16】
Figure 2004143049
【0030】
(式中、R2、R3およびR4は前記と同義である。)で表される5’−O−置換チミジンの精製法。
(4) R1がメチル基である上記項目(1)〜(3)に記載の精製法。
(5)R2が4,4’−ジメトキシトリチル基、R3がメチル基、R4が水素原子である上記項目(1)〜(3)の何れかに記載の精製法。
(6) R5がメチル基、R6がイソブチル基またはブトキシ基である上記項目(2)〜(3)の何れかに記載の精製法。
【0031】
【発明実施の形態】
以下、本発明を詳細に説明する。
一般式〔1〕で表わされるニトリル系溶媒おいて、R1における炭素数1〜4の低級アルキル基とは、メチル基、エチル基、n−プロピル基、i−プロピル基、n−ブチル基、i−ブチル基等が挙げられる。
【0032】
一般式〔2〕で表わされる5’−保護化チミジン類において、R2におけるトリチル基上の置換基は、無置換でもよいしそれぞれのフェニル基上の2位、3位、4位のいずれかの位置に置換基があってもよい。また、複数の位置に置換基があってもよい。またトリフェニル基のいずれのフェニル基に置換基があってもよく、複数のフェニル基に同一あるいは別の置換基があってもよい。
【0033】
置換基としてはたとえば、メチル基、エチル基、イソプロピル基などのアルキル基、メトキシ基、エトキシ基、n−プロピルオキシ基、i−プロピルオキシ基などのアルキルオキシ基、ニトロ基、アミノ基、メチルアミノ基、エチルアミノ基、n−プロピルアミノ基、i−プロピルアミノ基、ジメチルアミノ基、ジエチルアミノ基などの置換もしくは無置換アミノ基、フルオロ基、クロロ基、ブロモ基などのハロゲン基、ホルミル基、アセチル基、プロピオニル基、ベンゾイル基などのアシル基、ホルミルオキシ基、アセチルオキシ基、プロピオニルオキシ基、ベンゾイルオキシ基などのアシルオキシ基、ホルムアミド基、アセトアミド基、ベンズアミド基などのアミド基等が挙げられる。
【0034】
置換されてもよいトリチル基の例としては例えば、トリチル基、4−メトキシトリチル基、4,4’−ジメトキシトリチル基、4,4’,4’’−トリメトキシトリチル基、4−メチルトリチル基、4,4’−ジメチルトリチル基等が挙げられるがこれらに限定されるものではない。
【0035】
R3における炭素数1〜4のアルキル基とは、アルキル基が直鎖上でも分岐していてもよく、また環を形成していてもかまわない。またアルキル基上に別の置換基が置換していてもかまわない。具体的にはたとえば、メチル基、エチル基、n−プロピル基、i−プロピル基、ブチル基、シクロプロピル基、シクロプロピルメチル基、シクロペンチル基等が挙げられる。
【0036】
R4におけるハロゲン基とは、フッ素原子、塩素原子、臭素原子、ヨウ素原子を表す。R4における置換された水酸基とは、カルボン酸エステル、スルホン酸エステル、エーテル、ウレタン、シリル基などの一般的な水酸基の保護基となりうる置換基により置換された水酸基を表す。水酸基の保護基の例としては、メチル基、エチル基、イソプロピル基、n−ブチル基、i−ブチル基、t−ブチル基、ペンチル基、ベンジル基、2−メトキシベンジル基、3−メトキシベンジル基、4−メトキシベンジル基、2−メチルベンジル基、3−メチルベンジル基、4−メチルベンジル基、メトキシエチル基、エトキシエチル基、ベンジルオキシメチル基、ベンジルオキシエチル基、アセトキシメチル基、アセトキシエチル基、ベンゾイルオキシメチル基、ベンゾイルオキシエチル基、メトキシエトキシエチル基、プロパルギル基、アリル基等のアルキル基またはアルキル基の先にさらに置換されたアルキル基、フェニル基、2−メトキシフェニル基、3−メトキシフェニル基、4−メトキシフェニル基、4−フェニルフェニル基、2−ピリジニル基、3−ピリジニル基、4−ピリジニル基等のアリール基、ホルミル基、アセチル基、プロピオニル基、ベンゾイル基、2−メトキシベンゾイル基、3−メトキシベンゾイル基、4−メトキシベンゾイル基、2−メチルベンゾイル基、3−メチルベンゾイル基、4−メチルベンゾイル基、2−ニトロベンゾイル基、3−ニトロベンゾイル基、4−ニトロベンゾイル基、4−フェニルベンゾイル基、2−クロロベンゾイル基、3−クロロベンゾイル基、4−クロロベンゾイル基などのアシル基、アミノカルボニル基、ジメチルアミノカルボニル基、メチルアミノカルボニル基、エチルアミノカルボニル基、ジエチルアミノカルボニル基、フェニルアミノカルボニル基などのウレタン基、メタンスルホニル基、エタンスルホニル基、ベンゼンスルホニル基、2−メチルベンゼンスルホニル基、3−メチルベンゼンスルホニル基、4−メチルベンゼンスルホニル基、トリフルオロメタンスルホニル基、トリクロロメタンスルホニル基等のスルホン酸エステル基、トリメチルシリル基、トリエチルシリル基、t−ブチルジメチルシリル基、t−ブチルジフェニルシリル基などのシリル基が挙げられる。
【0037】
R4の置換された水酸基の例としてはたとえば、メトキシ基、エトキシ基、イソプロピルオキシ基、n−ブチルオキシ基、i−ブチルオキシ基、t−ブチルオキシ基、ペンチルオキシ基、ベンジルオキシ基、2−メトキシベンジルオキシ基、3−メトキシベンジルオキシ基、4−メトキシベンジルオキシ基、2−メチルベンジルオキシ基、3−メチルベンジルオキシ基、4−メチルベンジルオキシ基、メトキシエチルオキシ基、エトキシエチルオキシ基、ベンジルオキシメトキシ基、ベンジルオキシエトキシ基、アセトキシメトキシ基、アセトキシエトキシ基、ベンゾイルオキシメトキシ基、ベンゾイルオキシエトキシ基、メトキシエトキシエトキシ基、プロパルギルオキシ基、アリルオキシ基、フェニルオキシ基、2−メトキシフェニルオキシ基、3−メトキシフェニルオキシ基、4−メトキシフェニルオキシ基、4−フェニルフェニルオキシ基、2−ピリジニルオキシ基、3−ピリジニルオキシ基、4−ピリジニルオキシ基、ホルミルオキシ基、アセチルオキシ基、プロピオニルオキシ基、ベンゾイルオキシ基、2−メトキシベンゾイルオキシ基、3−メトキシベンゾイルオキシ基、4−メトキシベンゾイルオキシ基、2−メチルベンゾイルオキシ基、3−メチルベンゾイルオキシ基、4−メチルベンゾイルオキシ基、2−ニトロベンゾイルオキシ基、3−ニトロベンゾイルオキシ基、4−ニトロベンゾイルオキシ基、4−フェニルベンゾイルオキシ基、2−クロロベンゾイルオキシ基、3−クロロベンゾイルオキシ基、4−クロロベンゾイルオキシ基、アミノカルボニルオキシ基、ジメチルアミノカルボニルオキシ基、メチルアミノカルボニルオキシ基、エチルアミノカルボニルオキシ基、ジエチルアミノカルボニルオキシ基、フェニルアミノカルボニルオキシ基、メタンスルホニルオキシ基、エタンスルホニルオキシ基、ベンゼンスルホニルオキシ基、2−メチルベンゼンスルホニルオキシ基、3−メチルベンゼンスルホニルオキシ基、4−メチルベンゼンスルホニルオキシ基、トリフルオロメタンスルホニルオキシ基、トリクロロメタンスルホニルオキシ基、トリメチルシリルオキシ基、トリエチルシリルオキシ基、t−ブチルジメチルシリルオキシ基、t−ブチルジフェニルシリルオキシ基などが挙げられる。
【0038】
一般式〔3〕で表わされるカルボニル化合物において、R5、R6における炭素数1〜4のアルキル基としては、メチル基、エチル基、n−プロピル基、イソプロピル基、n−ブチル基、イソブチル基、t−ブチル基、n−ペンチル基、2−メチルブチル基、アミル基、n−ヘキシル基、シクロヘキシル基、4−シクロヘキシル基、n−ヘプチル基などが挙げられ、R6における炭素数1〜4のアルコキシ基としては、メトキシ基、エトキシ基、イソプロピルオキシ基、n−ブトキシ基、i−ブチルオキシ基、t−ブチルオキシ基、ペンチルオキシ基などがあげられる。
【0039】
カルボニル化合物の代表例としては、アセトン、2−ブタノン、3−ペンタノン、2,4−ジメチル−3−ペンタノン、4−メチル−2−ペンタノン、3−メチル−2−ブタノン、酢酸メチル、酢酸エチル、酢酸n−プロピル、酢酸イソプロピル、酢酸n−ブチル、酢酸t−ブチル、酢酸イソブチル、酢酸アミル、酢酸n−ペンチル、酢酸n−ヘキシル、酢酸シクロヘキシル、プロピオン酸n−プロピル、プロピオン酸イソプロピル等が挙げられる。
【0040】
一般式〔4〕で表わされる化合物の代表例としては、5’−O−(4,4’−ジメトキシトリチル)チミジン・0.5メチルイソブチルケトン複合体(m=2、n=1)、5’−O−(4,4’−ジメトキシトリチル)チミジン・0.5酢酸ブチル複合体(m=2、n=1)などが挙げられる。
【0041】
一般式〔1〕で示されるニトリル系溶媒は、通常単独で用いるが、混和可能な比率で組み合わせて用いることもできる。また、あらかじめ複数のニトリル系溶媒を組み合わせた混合溶媒を用いることもできる。
【0042】
さらに、これらの溶媒は単独のニトリル系溶媒または、混合溶媒に対して混和可能な比率で他の溶媒と混和して使用してもよい。混和の際に用いることのできる溶媒としては、メタノール、エタノール、イソプロパノール等のアルコール類、酢酸エチル,酢酸ブチルなどのエステル類、アセトン、メチルエチルケトン、メチルイソブチルケトンなどのケトン類、ジエチルエーテル、ジイソプロピルエーテル、ジオキサン、THFなどのエーテル類、ベンゼン、トルエン、クメン、キシレン、メシチレン、ジイソプロピルベンゼン、トリイソプロピルベンゼンなどの芳香族炭化水素、ジクロロメタン、クロロホルム、ジクロロエタン等のハロゲン化炭化水素類、ピリジン、ルチジン、キノリンなどのピリジン類、トリエチルアミン、トリブチルアミン等の3級アミン、DMF、DMI、DMSOなどの極性溶媒、水などが挙げられる。混和の際の比率はニトリル系溶媒に対し100重量%以下であるが、好ましくは20重量%以下であり、さらに好ましくは10重量%以下である。
【0043】
再結晶の際の溶媒量は、その溶液に対する一般式〔2〕又は一般式〔4〕で表される化合物の飽和溶解度以下であれば特に規定されないが、重量換算で該化合物1に対して3倍以上150倍以下が望ましく、さらに望ましくは5倍以上50倍以下である。
【0044】
再結晶は化合物を溶媒に加え、必要により反応液中の化合物を完全に加熱溶解しそのまま冷却することにより達成される。再結晶の際の温度は特に規定されないが、−10℃から溶媒の沸点の範囲が望ましい。また、通常は1回の再結晶で十分精製可能であるが、さらに繰り返し再結晶を行うことでより高純度にすることもできる。
【0045】
以上本発明により、5’−O− (4,4’−ジメトキシトリチル)チミジンの効率的な精製ができるようになった。
【0046】
【実施例】
以下に実施例をあげて本発明を具体的に説明するが、本発明はこれらによって限定されるものではない。
【0047】
実施例1
5’−O−(4,4’−ジメトキシトリチル)チミジンの製造
チミジン40.0g(0.165mol)をピリジン500mlに溶解した。4,4’−ジメトキシトリチルクロリド56.0g(0.165mol)を室温で添加した後、室温で3時間攪拌した。この反応液を逆相用オクタデシルシリカゲルカラムを用いてアセトニトリル/水(75/25)混合溶媒で溶離させ、UV検出器(254nm)で検出する高速液体クロマトグラフィーで分析した。次に、炭酸水素ナトリウム13.9gを加え、室温で30分間攪拌した後、約180gまで減圧下濃縮した。残留物に酢酸エチル1500ml及び水1500mlを加え、激しく攪拌した後、分液した。有機層を飽和炭酸水素ナトリウム水1500mlで2回洗浄し、次に飽和NaCl水1500mlで洗浄した。有機層をNaSO上で乾燥した後、減圧濃縮乾固し粗精製固体を得た。粗精製固体を高速液体クロマトグラフィーで分析した。粗精製固体をアセトニトリル800mlに加え加熱溶解した後、室温まで冷却して再結晶を行った。析出した固体を濾取し、55℃で恒量になるまで減圧乾燥した。この精製固体を高速液体クロマトグラフィーで分析した。5’−O− (4,4’−ジメトキシトリチル)チミジンの収率は85%であった。
【0048】
NMR:δ(CDCl) 8.7(S,1H)、7.6(S,1H),7.2−7.4(m,9H),6.8(m ,4H),6.4(t,1H),4.6(m,1H)、4.1(m,1H)、3.8(S,6H),3.4(m,2H)、2.4(m,2H)、1.5(S,3H)
【0049】
【表1】
Figure 2004143049
【0050】
実施例2
(1)5’−O−(4,4’−ジメトキシトリチル)チミジン・0.5メチルイソブチルケトン複合体の製造
チミジン40.0g(0.165mol)をピリジン500mlに溶解撹拌しつつ、ジメトキシトリチルクロリド56.0g(0.165mol)を添加し、室温で3時間撹拌した。炭酸水素ナトリウム16.7gを加え、室温で30分間撹拌後、溶媒を減圧で留去した。残留物にメチルイソブチルケトン500mlを加え撹拌しつつ、水500mlを加えて10分間撹拌した。次いで有機層を採り、水500mlで洗った。有機層を採り、溶媒を減圧で留去した。残留物をメチルイソブチルケトン900mlに加え加熱溶解後室温まで冷却して再結晶し、得られた結晶生成物を濾取した。次いで結晶生成物を50℃で真空乾燥したところ、その重量は67.3gであった。逆相用オクタデシルシリカゲルカラムを用いて、アセトニトリル/水(75/25)混合溶媒で溶離させ、UV検出器(254nm)で検出する高速液体クロマトグラフィーで分析したところ、純度は99.5%(面積%)、最大不純物は、3’,5’−O−ビス(4,4’−ジメトキシトリチル)チミジンの0.3%(面積%)であった。5’−O−(4,4’−ジメトキシトリチル)チミジン・0.5メチルイソブチルケトンの収率は67%であった。
【0051】
NMR:δ(CDCl) 8.7(S,1H)、7.6(S,1H),7.2−7.4(m,9H),6.8(m ,4H),6.4(t,1H),4.6(m,1H)、4.1(m,1H)、3.8(S,6H),3.4(m,2H)、2.4(m,3H,MIBKのCHCOの1H分を含む)、2.1(m,2H,MIBKのCHCO,CH)、1.5(S,3H)、0.9(d,3H,MIBKのCH).(MIBK:メチルイソブチルケトンの略)
IR:cm−1(KBrTablet) 3163、1698、1608、1509、1259、1177、1098、1033、830.
【0052】
(2)5’−O−(4,4’−ジメトキシトリチル)チミジンの製造
上記(1)で得られた5’−O−(4,4’−ジメトキシトリチル)チミジン・0.5メチルイソブチルケトン10.0gをアセトニトリル100mlに加え、加熱溶解後室温まで冷却して再結晶を行った。析出した固体を濾取し、55℃で恒量になるまで減圧乾燥し、5’−O−(4,4’−ジメトキシトリチル)チミジン8.28gを得た(収率90.4%)。逆相用オクタデシルシリカゲルカラムを用いて、アセトニトリル/水(75/25)混合溶媒で溶離させ、UV検出器(254nm)で検出する高速液体クロマトグラフィーで分析したところ、純度は99.7%(面積%)であった。メチルイソブチルケトンをガスクロマトグラフィー分析したところ、0.3重量%以下であった。
【0053】
NMR:δ(CDCl) 8.7(S,1H)、7.6(S,1H),7.2−7.4(m,9H),6.8(m ,4H),6.4(t,1H),4.6(m,1H)、4.1(m,1H)、3.8(S,6H),3.4(m,2H)、2.4(m,2H)、1.5(S,3H)
【0054】
実施例3
(1)5’−O−(4,4’−ジメトキシトリチル)チミジン・0.5酢酸n−ブチル複合体の製造
チミジン40.0g(0.165mol)をピリジン500mlに溶解撹拌しつつ、ジメトキシトリチルクロリド56.0g(0.165mol)を添加し、室温で3時間撹拌した。炭酸水素ナトリウム16.7gを加え、室温で30分間撹拌後、溶媒を減圧で留去した。残留物に酢酸n−ブチル500mlを加え撹拌しつつ、水500mlを加えて10分間撹拌した。次いで有機層を採り、水500mlで洗った。有機層を採り、溶媒を減圧で留去した。残留物を酢酸n−ブチル900mlに加え加熱溶解後室温まで冷却して再結晶し、得られた結晶生成物を濾取した。次いで結晶生成物を50℃で恒量となるまで真空乾燥したところ、その重量は74.6gであった。逆相用オクタデシルシリカゲルカラムを用いて、アセトニトリル/水(75/25)混合溶媒で溶離させ、UV検出器(254nm)で検出する高速液体クロマトグラフィー(HPLC)で分析したところ、純度は99.6%であった。最大不純物は、3’,5’−O−ビス(4,4’−ジメトキシトリチル)チミジンの0.3%(HPLCピーク面積%)であった。5’−O−(4,4’−ジメトキシトリチル)チミジン・0.5酢酸n−ブチルの収率は75%であった。
【0055】
NMR:δ(CDCl) 0.9(t,1.5H,酢酸n−ブチルのCH)、1.4(m,1H,酢酸n−ブチルのCH),1.5(s,3H)、1.6(m,1H,酢酸n−ブチルのCH),2.0(s ,1.5H,酢酸n−ブチルのCH),2.3(m,1H),2.4(m,1H)、2.6(m,1H,酢酸n−ブチルのOCH)、3.3(dd,1H),3.4(dd,1H)、3.8(s,6H)、4.1(m,1H)、4.6(m,1H)、6.4(m,1H)、6.8(m,4H)、7.3(m,7H)、7.4(m,2H)、7.6(s、1H)、8.9(s,1H).
【0056】
(2)5’−O−(4,4’−ジメトキシトリチル)チミジンの製造
上記(1)で得られた5’−O−(4,4’−ジメトキシトリチル)チミジン・0.5酢酸n−ブチル10.0gをアセトニトリル100mlに加え、加熱溶解した後室温まで冷却して再結晶した。析出した固体を濾取し、55℃で恒量になるまで減圧乾燥し、5’−O−(4,4’−ジメトキシトリチル)チミジン8.3gを得た(収率90%)。逆相用オクタデシルシリカゲルカラムを用いて、アセトニトリル/水(75/25)混合溶媒で溶離させ、UV検出器(254nm)で検出する高速液体クロマトグラフィーで分析したところ、純度は99.7%(面積%)であった。酢酸n−ブチルをガスクロマトグラフィー分析したところ、0.3重量%以下であった。
【0057】
NMR:δ(CDCl) 8.7(S,1H)、7.6(S,1H),7.2−7.4(m,9H),6.8(m ,4H),6.4(t,1H),4.6(m,1H)、4.1(m,1H)、3.8(S,6H),3.4(m,2H)、2.4(m,2H)、1.5(S,3H)
【0058】
【発明の効果】
本発明により、大量製造可能な方法を用いて、従来の方法に比べ効率的に高純度の5’−O−(4,4’−ジメトキシトリチル)チミジンを製造することができるようになった。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a method for purifying 5′-O-substituted thymidine.
[0002]
[Prior art]
In recent years, antisense DNA drugs and the like have been rapidly developed with the progress of genomic drug discovery. Along with this, the demand for a DNA oligomer as a raw material and a protected deoxynucleoside as a raw material for the oligomer is increasing. On the other hand, for pharmaceutical applications, it is necessary to use an intermediate product of extremely high purity in order to minimize the formation of by-products due to impurities contained therein.
[0003]
Heretofore, 5'-O- (4,4'-dimethoxytrityl) thymidine has been disclosed in JP-A-58-180500, J. Am. Am. Chem. Soc. 85, 3821 (1963), Protein Nucleic Acid Enzyme Vol. 26, No. As is apparent from examples such as 4,531 (1981), it has been purified by a recrystallization method using benzene or a mixed solvent of benzene and hexane. Benzene is particularly harmful and has to be said to be very problematic in future mass production and mass supply. In addition, when actually performed, it is not practical because it gels and takes in impurities together with the solvent. In Japanese Patent Application Laid-Open No. 11-511480, purification is performed by recrystallization with a mixed solvent of ethyl acetate / hexane, but it is industrially difficult to appropriately adjust the ratio of ethyl acetate to hexane. If it is incorrect, the oil is easily turned into oil or a viscous precipitate is formed, so that the purification tends to fail. Methods in Enzymology Vol. Although there is purification by column chromatography using silica gel such as 65 Nucleic Acids Part I (1980), column chromatography is not suitable for mass production and mass supply. In addition, chloroform, which is particularly harmful, is used for the eluent. As other purification methods, the suspension method is reported in PCT application WO20039138, and the reprecipitation method is reported in PTC application WO200075154, all using dichloromethane as a solvent. Although purification is performed using a mixed solvent, 5′-O- (4,4′-dimethoxytrityl) thymidine is a mixture of a soluble solvent and an insoluble solvent, and it is industrially necessary to appropriately adjust the quantitative ratio. However, there is a problem that if the amount ratio is wrong, the oil is easily turned into oil or a viscous precipitate is formed to easily cause the purification to fail.
[0004]
Therefore, as a result of examining various solvents, when a carbonyl solvent represented by methyl isobutyl ketone or butyl acetate is used, recrystallization with a single solvent, which has not been reported previously, becomes possible, and the purification ability is extremely high. Turned out to be high. If the purification method using these solvents is used, an impurity having a trityl group substituted at both the 5 ′ and 3 ′ positions and a substituted isomer having a trityl group substituted at the 3 ′ position have been difficult to purify. Can be easily removed. However, the recrystallized product was obtained in a crystal form in which a recrystallization solvent such as methyl isobutyl ketone or butyl acetate was embraced, and removal of the immersion solvent was impossible by ordinary methods such as drying under reduced pressure.
[0005]
[Patent Document 1] JP-A-58-180500
[Patent Document 2] Japanese Patent Publication No. 11-511480
[Patent document 3] PCT application WO20039138
[Patent Document 4] PTC application WO200075154
[Non-Patent Document 1] Am. Chem. Soc. , 85, 3821 (1963)
[0010]
[Non-patent document 2] Protein nucleic acid enzyme Vol. 26, No. 4,531 (1981)
[0011]
[Non-Patent Document 3] Methods in Enzymology Vol. 65 Nucleic Acids Part I (1980)
[0012]
[Problems to be solved by the invention]
In view of the conventional problems, it is an object of the present invention to provide a method for producing 5′-O-substituted thymidine of extremely high purity, which is efficient and does not require special equipment.
[0013]
[Means for Solving the Problems]
The present inventors have conducted intensive studies on the above-mentioned problems, and as a result, it was found that 5′-O- (4,4′-dimethoxytrityl) thymidine can be purified by a purification method by recrystallization using acetonitrile, and that no solvent is impregnated. And completed the present invention.
[0014]
That is, the present invention includes the following embodiments.
(1) General formula [1] [Chemical formula 9]
[0015]
Embedded image
Figure 2004143049
[0016]
(Wherein, R1 represents an alkyl group having 1 to 4 carbon atoms), and recrystallized using a solvent represented by the following general formula [2]:
[0017]
Embedded image
Figure 2004143049
[0018]
(Wherein, R2 represents an optionally substituted trityl group, R3 represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, and R4 represents a hydrogen atom, a halogen atom, or an optionally substituted hydroxyl group). A method for purifying the represented 5'-O-substituted thymidine.
(2) General formula [3] [Chemical formula 11]
[0019]
Embedded image
Figure 2004143049
[0020]
(Wherein R5 represents an alkyl group having 1 to 4 carbon atoms, and R6 represents an alkyl group having 1 to 4 carbon atoms or an alkoxy group having 1 to 4 carbon atoms). After that, the general formula [1] [Formula 12]
[0021]
Embedded image
Figure 2004143049
[0022]
(Wherein, R1 has the same meaning as described above), characterized by being recrystallized using a solvent represented by the following general formula [2]:
[0023]
Embedded image
Figure 2004143049
[0024]
(Wherein, R2, R3 and R4 have the same meanings as described above.) A method for purifying 5′-O-substituted thymidine represented by the formula:
(3) General formula [4]
[0025]
Embedded image
Figure 2004143049
[0026]
(Wherein, m and n are each independently an arbitrary integer, and R 2, R 3, R 4, R 5 and R 6 have the same meanings as described above) by a general formula [1]
[0027]
Embedded image
Figure 2004143049
[0028]
(Wherein, R1 has the same meaning as described above), characterized by being recrystallized using a solvent represented by the following general formula [2]:
[0029]
Embedded image
Figure 2004143049
[0030]
(Wherein, R2, R3 and R4 have the same meanings as described above.) A method for purifying 5′-O-substituted thymidine represented by the formula:
(4) The purification method according to the above items (1) to (3), wherein R1 is a methyl group.
(5) The purification method according to any one of the above items (1) to (3), wherein R2 is a 4,4'-dimethoxytrityl group, R3 is a methyl group, and R4 is a hydrogen atom.
(6) The purification method according to any one of the above items (2) to (3), wherein R5 is a methyl group, and R6 is an isobutyl group or a butoxy group.
[0031]
DETAILED DESCRIPTION OF THE INVENTION
Hereinafter, the present invention will be described in detail.
In the nitrile solvent represented by the general formula [1], the lower alkyl group having 1 to 4 carbon atoms in R1 means a methyl group, an ethyl group, an n-propyl group, an i-propyl group, an n-butyl group, an i-butyl group. -Butyl group and the like.
[0032]
In the 5'-protected thymidine represented by the general formula [2], the substituent on the trityl group in R2 may be unsubstituted or any one of the 2-, 3-, and 4-positions on each phenyl group. There may be a substituent at the position. Further, a substituent may be present at a plurality of positions. Further, any phenyl group of the triphenyl group may have a substituent, and a plurality of phenyl groups may have the same or different substituents.
[0033]
Examples of the substituent include an alkyl group such as a methyl group, an ethyl group and an isopropyl group; an alkyloxy group such as a methoxy group, an ethoxy group, an n-propyloxy group and an i-propyloxy group; a nitro group; an amino group; Group, ethylamino group, n-propylamino group, i-propylamino group, substituted or unsubstituted amino group such as dimethylamino group, diethylamino group, halogen group such as fluoro group, chloro group, bromo group, formyl group, acetyl Groups, an acyl group such as a propionyl group and a benzoyl group, an acyloxy group such as a formyloxy group, an acetyloxy group, a propionyloxy group and a benzoyloxy group, and an amide group such as a formamide group, an acetamido group and a benzamide group.
[0034]
Examples of the optionally substituted trityl group include, for example, a trityl group, a 4-methoxytrityl group, a 4,4′-dimethoxytrityl group, a 4,4 ′, 4 ″ -trimethoxytrityl group, a 4-methyltrityl group , 4,4'-dimethyltrityl and the like, but are not limited thereto.
[0035]
The alkyl group having 1 to 4 carbon atoms in R3 may be such that the alkyl group may be linear or branched, or may form a ring. Further, another substituent may be substituted on the alkyl group. Specific examples include a methyl group, an ethyl group, an n-propyl group, an i-propyl group, a butyl group, a cyclopropyl group, a cyclopropylmethyl group, a cyclopentyl group, and the like.
[0036]
The halogen group for R4 represents a fluorine atom, a chlorine atom, a bromine atom or an iodine atom. The substituted hydroxyl group in R4 represents a hydroxyl group substituted by a substituent which can be a general hydroxyl-protecting group such as a carboxylic acid ester, a sulfonic acid ester, an ether, a urethane or a silyl group. Examples of the hydroxyl-protecting group include methyl, ethyl, isopropyl, n-butyl, i-butyl, t-butyl, pentyl, benzyl, 2-methoxybenzyl, and 3-methoxybenzyl. , 4-methoxybenzyl, 2-methylbenzyl, 3-methylbenzyl, 4-methylbenzyl, methoxyethyl, ethoxyethyl, benzyloxymethyl, benzyloxyethyl, acetoxymethyl, acetoxyethyl An alkyl group such as a benzoyloxymethyl group, a benzoyloxyethyl group, a methoxyethoxyethyl group, a propargyl group, an allyl group or an alkyl group further substituted with an alkyl group, a phenyl group, a 2-methoxyphenyl group, or a 3-methoxy Phenyl group, 4-methoxyphenyl group, 4-phenylphenyl group, Aryl groups such as -pyridinyl group, 3-pyridinyl group and 4-pyridinyl group, formyl group, acetyl group, propionyl group, benzoyl group, 2-methoxybenzoyl group, 3-methoxybenzoyl group, 4-methoxybenzoyl group, 2- Methylbenzoyl, 3-methylbenzoyl, 4-methylbenzoyl, 2-nitrobenzoyl, 3-nitrobenzoyl, 4-nitrobenzoyl, 4-phenylbenzoyl, 2-chlorobenzoyl, 3-chlorobenzoyl Groups, acyl groups such as 4-chlorobenzoyl group, aminocarbonyl group, dimethylaminocarbonyl group, methylaminocarbonyl group, ethylaminocarbonyl group, diethylaminocarbonyl group, urethane group such as phenylaminocarbonyl group, methanesulfonyl group, ethanesulfonyl Base Sulfonic acid ester groups such as benzenesulfonyl group, 2-methylbenzenesulfonyl group, 3-methylbenzenesulfonyl group, 4-methylbenzenesulfonyl group, trifluoromethanesulfonyl group, trichloromethanesulfonyl group, trimethylsilyl group, triethylsilyl group, t- And silyl groups such as butyldimethylsilyl group and t-butyldiphenylsilyl group.
[0037]
Examples of the substituted hydroxyl group for R4 include, for example, methoxy group, ethoxy group, isopropyloxy group, n-butyloxy group, i-butyloxy group, t-butyloxy group, pentyloxy group, benzyloxy group, 2-methoxybenzyloxy Group, 3-methoxybenzyloxy group, 4-methoxybenzyloxy group, 2-methylbenzyloxy group, 3-methylbenzyloxy group, 4-methylbenzyloxy group, methoxyethyloxy group, ethoxyethyloxy group, benzyloxymethoxy Group, benzyloxyethoxy group, acetoxymethoxy group, acetoxyethoxy group, benzoyloxymethoxy group, benzoyloxyethoxy group, methoxyethoxyethoxy group, propargyloxy group, allyloxy group, phenyloxy group, 2-methoxyphenyloxy C, 3-methoxyphenyloxy, 4-methoxyphenyloxy, 4-phenylphenyloxy, 2-pyridinyloxy, 3-pyridinyloxy, 4-pyridinyloxy, formyloxy, acetyloxy, propionyloxy Benzoyloxy group, 2-methoxybenzoyloxy group, 3-methoxybenzoyloxy group, 4-methoxybenzoyloxy group, 2-methylbenzoyloxy group, 3-methylbenzoyloxy group, 4-methylbenzoyloxy group, 2-nitro Benzoyloxy, 3-nitrobenzoyloxy, 4-nitrobenzoyloxy, 4-phenylbenzoyloxy, 2-chlorobenzoyloxy, 3-chlorobenzoyloxy, 4-chlorobenzoyloxy, aminocarbonyloxy Group, dimethylaminocarbonyloxy group, methylaminocarbonyloxy group, ethylaminocarbonyloxy group, diethylaminocarbonyloxy group, phenylaminocarbonyloxy group, methanesulfonyloxy group, ethanesulfonyloxy group, benzenesulfonyloxy group, 2-methylbenzene Sulfonyloxy group, 3-methylbenzenesulfonyloxy group, 4-methylbenzenesulfonyloxy group, trifluoromethanesulfonyloxy group, trichloromethanesulfonyloxy group, trimethylsilyloxy group, triethylsilyloxy group, t-butyldimethylsilyloxy group, t -Butyldiphenylsilyloxy group and the like.
[0038]
In the carbonyl compound represented by the general formula [3], the alkyl group having 1 to 4 carbon atoms in R5 and R6 includes a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a t-group. -Butyl group, n-pentyl group, 2-methylbutyl group, amyl group, n-hexyl group, cyclohexyl group, 4-cyclohexyl group, n-heptyl group, and the like. As the alkoxy group having 1 to 4 carbon atoms in R6, Represents a methoxy group, an ethoxy group, an isopropyloxy group, an n-butoxy group, an i-butyloxy group, a t-butyloxy group, a pentyloxy group and the like.
[0039]
Representative examples of the carbonyl compound include acetone, 2-butanone, 3-pentanone, 2,4-dimethyl-3-pentanone, 4-methyl-2-pentanone, 3-methyl-2-butanone, methyl acetate, ethyl acetate, N-propyl acetate, isopropyl acetate, n-butyl acetate, t-butyl acetate, isobutyl acetate, amyl acetate, n-pentyl acetate, n-hexyl acetate, cyclohexyl acetate, n-propyl propionate, isopropyl propionate and the like. .
[0040]
Typical examples of the compound represented by the general formula [4] include a 5′-O- (4,4′-dimethoxytrityl) thymidine / 0.5 methyl isobutyl ketone complex (m = 2, n = 1), '-O- (4,4'-dimethoxytrityl) thymidine / 0.5 butyl acetate complex (m = 2, n = 1).
[0041]
The nitrile solvents represented by the general formula [1] are usually used alone, but may be used in combination at a miscible ratio. Further, a mixed solvent in which a plurality of nitrile solvents are combined in advance can be used.
[0042]
Further, these solvents may be used as a single nitrile solvent or as a mixture with another solvent at a ratio compatible with the mixed solvent. Solvents that can be used for mixing include alcohols such as methanol, ethanol and isopropanol, esters such as ethyl acetate and butyl acetate, ketones such as acetone, methyl ethyl ketone and methyl isobutyl ketone, diethyl ether, diisopropyl ether, and the like. Ethers such as dioxane and THF, aromatic hydrocarbons such as benzene, toluene, cumene, xylene, mesitylene, diisopropylbenzene and triisopropylbenzene, halogenated hydrocarbons such as dichloromethane, chloroform and dichloroethane, pyridine, lutidine and quinoline Tertiary amines such as pyridines, triethylamine and tributylamine, polar solvents such as DMF, DMI and DMSO, and water. The mixing ratio is 100% by weight or less, preferably 20% by weight or less, more preferably 10% by weight or less, based on the nitrile solvent.
[0043]
The amount of the solvent at the time of recrystallization is not particularly limited as long as it is equal to or lower than the saturation solubility of the compound represented by the general formula [2] or [4] in the solution. It is desirably not less than twice and not more than 150 times, and more desirably not less than 5 times and not more than 50 times.
[0044]
Recrystallization is achieved by adding the compound to a solvent, and if necessary, completely dissolving the compound in the reaction solution by heating and cooling. The temperature at the time of recrystallization is not particularly limited, but is preferably in the range of −10 ° C. to the boiling point of the solvent. In general, purification can be sufficiently performed by one recrystallization, but higher purity can be obtained by further recrystallization.
[0045]
As described above, according to the present invention, 5′-O- (4,4′-dimethoxytrityl) thymidine can be efficiently purified.
[0046]
【Example】
Hereinafter, the present invention will be described specifically with reference to Examples, but the present invention is not limited thereto.
[0047]
Example 1
Preparation of 5′-O- (4,4′-dimethoxytrityl) thymidine 40.0 g (0.165 mol) of thymidine was dissolved in 500 ml of pyridine. After adding 56.0 g (0.165 mol) of 4,4'-dimethoxytrityl chloride at room temperature, the mixture was stirred at room temperature for 3 hours. The reaction solution was eluted with a mixed solvent of acetonitrile / water (75/25) using an octadecyl silica gel column for reversed phase, and analyzed by high performance liquid chromatography detected with a UV detector (254 nm). Next, 13.9 g of sodium hydrogen carbonate was added, and the mixture was stirred at room temperature for 30 minutes, and then concentrated under reduced pressure to about 180 g. 1500 ml of ethyl acetate and 1500 ml of water were added to the residue, and the mixture was vigorously stirred and then separated. The organic layer was washed twice with 1500 ml of a saturated aqueous solution of sodium bicarbonate and then with 1500 ml of a saturated aqueous solution of NaCl. The organic layer was dried over Na 2 SO 4 and concentrated to dryness under reduced pressure to obtain a crude solid. The crude solid was analyzed by high performance liquid chromatography. The crude solid was added to 800 ml of acetonitrile, dissolved by heating, and then cooled to room temperature for recrystallization. The precipitated solid was collected by filtration and dried at 55 ° C. under reduced pressure until the weight became constant. This purified solid was analyzed by high performance liquid chromatography. The yield of 5'-O- (4,4'-dimethoxytrityl) thymidine was 85%.
[0048]
NMR: δ (CDCl 3 ) 8.7 (S, 1H), 7.6 (S, 1H), 7.2-7.4 (m, 9H), 6.8 (m, 4H), 6.4. (T, 1H), 4.6 (m, 1H), 4.1 (m, 1H), 3.8 (S, 6H), 3.4 (m, 2H), 2.4 (m, 2H) , 1.5 (S, 3H)
[0049]
[Table 1]
Figure 2004143049
[0050]
Example 2
(1) Preparation of 5'-O- (4,4'-dimethoxytrityl) thymidine / 0.5 methyl isobutyl ketone complex 40.0 g (0.165 mol) of thymidine was dissolved in 500 ml of pyridine and stirred while dimethoxytrityl chloride was dissolved. 56.0 g (0.165 mol) was added, and the mixture was stirred at room temperature for 3 hours. After adding 16.7 g of sodium hydrogen carbonate and stirring at room temperature for 30 minutes, the solvent was distilled off under reduced pressure. To the residue was added 500 ml of methyl isobutyl ketone, and with stirring, 500 ml of water was added and the mixture was stirred for 10 minutes. Then the organic layer was taken and washed with 500 ml of water. The organic layer was collected, and the solvent was distilled off under reduced pressure. The residue was added to 900 ml of methyl isobutyl ketone, dissolved by heating, cooled to room temperature and recrystallized, and the obtained crystal product was collected by filtration. Next, the crystal product was vacuum-dried at 50 ° C., and the weight was 67.3 g. The product was eluted with a mixed solvent of acetonitrile / water (75/25) using an octadecyl silica gel column for reversed phase, and analyzed by high performance liquid chromatography detected with a UV detector (254 nm). The purity was 99.5% (area). %), The largest impurity was 0.3% (area%) of 3 ', 5'-O-bis (4,4'-dimethoxytrityl) thymidine. The yield of 5′-O- (4,4′-dimethoxytrityl) thymidine.0.5 methyl isobutyl ketone was 67%.
[0051]
NMR: δ (CDCl 3 ) 8.7 (S, 1H), 7.6 (S, 1H), 7.2-7.4 (m, 9H), 6.8 (m, 4H), 6.4. (T, 1H), 4.6 (m, 1H), 4.1 (m, 1H), 3.8 (S, 6H), 3.4 (m, 2H), 2.4 (m, 3H, MIBK contains 1H of CH 2 CO), 2.1 (m, 2H, CH 3 CO, CH of MIBK), 1.5 (S, 3H), 0.9 (d, 3H, CH 3 of MIBK) ). (MIBK: abbreviation for methyl isobutyl ketone)
IR: cm < -1 > (KBrTablet) 3163, 1698, 1608, 1509, 1259, 1177, 1098, 1033, 830.
[0052]
(2) Production of 5'-O- (4,4'-dimethoxytrityl) thymidine 5'-O- (4,4'-dimethoxytrityl) thymidine / 0.5 methyl isobutyl ketone obtained in (1) above 10.0 g was added to 100 ml of acetonitrile, dissolved by heating, cooled to room temperature, and recrystallized. The precipitated solid was collected by filtration and dried under reduced pressure at 55 ° C. until a constant weight was obtained, thereby obtaining 8.28 g of 5′-O- (4,4′-dimethoxytrityl) thymidine (yield 90.4%). The product was eluted with a mixed solvent of acetonitrile / water (75/25) using an octadecyl silica gel column for reversed phase, and analyzed by high performance liquid chromatography detected with a UV detector (254 nm). The purity was 99.7% (area). %)Met. Gas chromatographic analysis of methyl isobutyl ketone showed 0.3% by weight or less.
[0053]
NMR: δ (CDCl 3 ) 8.7 (S, 1H), 7.6 (S, 1H), 7.2-7.4 (m, 9H), 6.8 (m, 4H), 6.4. (T, 1H), 4.6 (m, 1H), 4.1 (m, 1H), 3.8 (S, 6H), 3.4 (m, 2H), 2.4 (m, 2H) , 1.5 (S, 3H)
[0054]
Example 3
(1) Preparation of 5'-O- (4,4'-dimethoxytrityl) thymidine / 0.5-n-butyl acetate complex A solution of 40.0 g (0.165 mol) of thymidine in 500 ml of pyridine was stirred while dimethoxytrityl was dissolved. 56.0 g (0.165 mol) of chloride was added, and the mixture was stirred at room temperature for 3 hours. After adding 16.7 g of sodium hydrogen carbonate and stirring at room temperature for 30 minutes, the solvent was distilled off under reduced pressure. To the residue, 500 ml of water was added while stirring and adding 500 ml of n-butyl acetate, and the mixture was stirred for 10 minutes. Then the organic layer was taken and washed with 500 ml of water. The organic layer was collected, and the solvent was distilled off under reduced pressure. The residue was added to 900 ml of n-butyl acetate, dissolved by heating, cooled to room temperature and recrystallized, and the obtained crystal product was collected by filtration. Next, the crystal product was vacuum-dried at 50 ° C. until a constant weight was obtained, and its weight was 74.6 g. The product was eluted with a mixed solvent of acetonitrile / water (75/25) using an octadecyl silica gel column for reversed phase, and analyzed by high performance liquid chromatography (HPLC) using a UV detector (254 nm) to find that the purity was 99.6. %Met. The maximum impurity was 0.3% (HPLC peak area%) of 3 ', 5'-O-bis (4,4'-dimethoxytrityl) thymidine. The yield of 5'-O- (4,4'-dimethoxytrityl) thymidine.0.5 n-butyl acetate was 75%.
[0055]
NMR: δ (CDCl 3) 0.9 (t, 1.5H, CH 3 of acetate n- butyl), 1.4 (m, 1H, acetate n- butyl CH 2), 1.5 (s, 3H ), 1.6 (m, 1H, CH 2 acetate n- butyl), 2.0 (s, 1.5H, CH 3 of acetate n- butyl), 2.3 (m, 1H) , 2.4 (m, 1H), 2.6 ( m, 1H, OCH 2 acetate n- butyl), 3.3 (dd, 1H) , 3.4 (dd, 1H), 3.8 (s, 6H), 4.1 (m, 1H), 4.6 (m, 1H), 6.4 (m, 1H), 6.8 (m, 4H), 7.3 (m, 7H), 7.4 (m , 2H), 7.6 (s, 1H), 8.9 (s, 1H).
[0056]
(2) Production of 5'-O- (4,4'-dimethoxytrityl) thymidine 5'-O- (4,4'-dimethoxytrityl) thymidine.0.5-acetic acid n- obtained in the above (1) 10.0 g of butyl was added to 100 ml of acetonitrile, dissolved by heating, cooled to room temperature, and recrystallized. The precipitated solid was collected by filtration and dried under reduced pressure at 55 ° C. until the weight became constant, to obtain 8.3 g of 5′-O- (4,4′-dimethoxytrityl) thymidine (yield 90%). The product was eluted with a mixed solvent of acetonitrile / water (75/25) using an octadecyl silica gel column for reversed phase, and analyzed by high performance liquid chromatography detected with a UV detector (254 nm). The purity was 99.7% (area). %)Met. Gas chromatography analysis of n-butyl acetate revealed that it was 0.3% by weight or less.
[0057]
NMR: δ (CDCl 3 ) 8.7 (S, 1H), 7.6 (S, 1H), 7.2-7.4 (m, 9H), 6.8 (m, 4H), 6.4. (T, 1H), 4.6 (m, 1H), 4.1 (m, 1H), 3.8 (S, 6H), 3.4 (m, 2H), 2.4 (m, 2H) , 1.5 (S, 3H)
[0058]
【The invention's effect】
According to the present invention, high purity 5′-O- (4,4′-dimethoxytrityl) thymidine can be produced more efficiently than conventional methods using a method which can be mass-produced.

Claims (6)

一般式〔1〕[化1]
Figure 2004143049
(式中、R1は炭素数1〜4のアルキル基を表す。)で表される溶媒を用いて再結晶することを特徴とする、一般式〔2〕[化2]
Figure 2004143049
(式中、R2は置換されてもよいトリチル基を、R3は水素原子または炭素数1〜4のアルキル基を、R4は水素原子、ハロゲン原子、もしくは置換されていてもよい水酸基を表す)で表される5’−O−置換チミジンの精製法。
General formula [1] [Formula 1]
Figure 2004143049
(Wherein R1 represents an alkyl group having 1 to 4 carbon atoms), and recrystallized using a solvent represented by the following general formula [2]:
Figure 2004143049
(Wherein, R2 represents an optionally substituted trityl group, R3 represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, and R4 represents a hydrogen atom, a halogen atom, or an optionally substituted hydroxyl group). A method for purifying the represented 5'-O-substituted thymidine.
一般式〔3〕[化3]
Figure 2004143049
(式中、R5は炭素数1〜4のアルキル基を、R6は炭素数1〜4のアルキル基もしくは炭素数1〜4のアルコキシ基を表す)で表されるカルボニル系溶媒で再結晶を行った後、一般式〔1〕[化4]
Figure 2004143049
(式中、R1は前記と同義である。)で表される溶媒を用いて再結晶することを特徴とする、一般式〔2〕[化5]
Figure 2004143049
(式中、R2、R3およびR4は前記と同義である。)で表される5’−O−置換チミジンの精製法。
General formula [3] [Chemical formula 3]
Figure 2004143049
(Wherein R5 represents an alkyl group having 1 to 4 carbon atoms, and R6 represents an alkyl group having 1 to 4 carbon atoms or an alkoxy group having 1 to 4 carbon atoms). After that, the general formula [1] [Formula 4]
Figure 2004143049
(Wherein, R1 has the same meaning as described above), characterized by being recrystallized using a solvent represented by the following general formula [2]:
Figure 2004143049
(Wherein, R2, R3 and R4 have the same meanings as described above).
一般式〔4〕[化6]
Figure 2004143049
(式中、mおよびnはそれぞれ独立して任意の整数、R2、R3、R4、R5およびR6は前記と同義である)で表される化合物を一般式〔1〕[化7]
Figure 2004143049
(式中、R1は前記と同義である。)で表される溶媒を用いて再結晶することを特徴とする、一般式〔2〕[化8]
Figure 2004143049
(式中、R2、R3およびR4は前記と同義である。)で表される5’−O−置換チミジンの精製法。
General formula [4] [Chemical formula 6]
Figure 2004143049
(Wherein m and n are each independently an arbitrary integer, and R 2, R 3, R 4, R 5 and R 6 are as defined above) by a compound represented by the general formula [1]
Figure 2004143049
(Wherein, R1 has the same meaning as described above), characterized by being recrystallized using a solvent represented by the following general formula [2]:
Figure 2004143049
(Wherein, R2, R3 and R4 have the same meanings as described above).
R1がメチル基である請求項1〜3の何れか一項に記載の精製法。The purification method according to any one of claims 1 to 3, wherein R1 is a methyl group. R2が4,4’−ジメトキシトリチル基、R3がメチル基、R4が水素原子である請求項1〜3の何れか一項に記載の精製法。The purification method according to any one of claims 1 to 3, wherein R2 is a 4,4'-dimethoxytrityl group, R3 is a methyl group, and R4 is a hydrogen atom. R5がメチル基、R6がイソブチル基またはブトキシ基である請求項2から3に記載の精製法。The purification method according to claim 2, wherein R5 is a methyl group, and R6 is an isobutyl group or a butoxy group.
JP2002306776A 2002-10-22 2002-10-22 Method for purifying 5'-O-substituted thymidine Expired - Fee Related JP4424900B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002306776A JP4424900B2 (en) 2002-10-22 2002-10-22 Method for purifying 5'-O-substituted thymidine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002306776A JP4424900B2 (en) 2002-10-22 2002-10-22 Method for purifying 5'-O-substituted thymidine

Publications (2)

Publication Number Publication Date
JP2004143049A true JP2004143049A (en) 2004-05-20
JP4424900B2 JP4424900B2 (en) 2010-03-03

Family

ID=32453432

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002306776A Expired - Fee Related JP4424900B2 (en) 2002-10-22 2002-10-22 Method for purifying 5'-O-substituted thymidine

Country Status (1)

Country Link
JP (1) JP4424900B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7875412B2 (en) 2006-04-03 2011-01-25 Orient Chemical Industries, Ltd. Positive electrified charge control agent and positive electrified toner for developing electrostatic image

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7875412B2 (en) 2006-04-03 2011-01-25 Orient Chemical Industries, Ltd. Positive electrified charge control agent and positive electrified toner for developing electrostatic image

Also Published As

Publication number Publication date
JP4424900B2 (en) 2010-03-03

Similar Documents

Publication Publication Date Title
JP7045669B2 (en) Method for synthesizing ribonucleic acid H-phosphonate monomer and oligonucleotide synthesis using this monomer
JP4424900B2 (en) Method for purifying 5&#39;-O-substituted thymidine
US8158774B2 (en) Method for introducing a nucleic-acid protecting group
EP1258489B1 (en) Method for purifying 5&#39;-protected thymidines
JP4071991B2 (en) Purification method and novel derivative of 5&#39;-protected thymidines
JP4326841B2 (en) Method for purifying protected 2&#39;-deoxycytidines
EP1253154B1 (en) Method for purifying 5&#39;-protected 2&#39;-deoxypurine nucleosides
JP2013531665A (en) Novel method using N-thio compounds for oligonucleotide synthesis
JP2007291100A (en) Process for preparing gemcitabine and associated intermediate
WO2021177123A1 (en) Artificial nucleic acid
JP3983085B2 (en) Method for producing inclusion compounds of 5&#39;-protected 2&#39;-deoxypurine nucleosides
WO2004052908A1 (en) Process for producing phosphoroamidite
JP2006248956A (en) Trityl-type compound
JP2003073395A (en) Isolation and purification of n-acylated purine nucleoside derivative
JP3883486B2 (en) Method for isolating and purifying 5&#39;-position protected purine nucleoside derivatives
JP3868235B2 (en) Method for producing 2,2&#39;-anhydronucleic acid compound derivative
JPH09124687A (en) Vinylated deoxyguanosine derivative
WO2001079248A1 (en) Process for the preparation of cytidine derivatives
JP2004203819A (en) Method for manufacturing n4-acylcytidine derivative
JPWO2010079813A1 (en) Method for producing inosine derivative
JPH0967392A (en) Vinylated deoxyguanosine derivative
JP2003306496A (en) Method of preparation of 5&#39;-position-protected 2&#39;- deoxycytidine
JP2001226394A (en) METHOD FOR PRODUCING 2&#39;-DEOXY-beta-GUANOSINE AND ITS INTERMEDIATE
JP2001354692A (en) Method for producing cytidine derivative

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050715

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20071018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090414

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090630

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090908

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091201

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20091208

R150 Certificate of patent (=grant) or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121218

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121218

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131218

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees